GALAPAGOS NV/S (NASDAQ:GLPG) gapped down prior to trading on Friday after Royal Bank of Canada lowered their price target on the stock from $135.00 to $131.00. The stock had previously closed at $138.50, but opened at $128.70. Royal Bank of Canada currently has a sector perform rating on the stock. GALAPAGOS NV/S shares last traded at $129.38, with a volume of 2,933 shares traded.
Other analysts also recently issued research reports about the company. Zacks Investment Research downgraded GALAPAGOS NV/S from a “hold” rating to a “sell” rating in a research report on Thursday, August 13th. Jefferies Financial Group downgraded shares of GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a research note on Tuesday, August 25th. BidaskClub upgraded shares of GALAPAGOS NV/S from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 17th. Bank of America decreased their target price on shares of GALAPAGOS NV/S from $148.00 to $134.00 and set an “underperform” rating on the stock in a research report on Friday, August 21st. Finally, Morgan Stanley increased their price target on shares of GALAPAGOS NV/S from $158.00 to $159.00 and gave the stock an “equal weight” rating in a research report on Tuesday, October 13th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $188.46.
Several large investors have recently made changes to their positions in GLPG. Morgan Stanley lifted its position in GALAPAGOS NV/S by 68.0% during the 1st quarter. Morgan Stanley now owns 121,181 shares of the biotechnology company’s stock worth $23,742,000 after buying an additional 49,053 shares in the last quarter. Federated Hermes Inc. lifted its position in shares of GALAPAGOS NV/S by 1.1% during the second quarter. Federated Hermes Inc. now owns 1,421,640 shares of the biotechnology company’s stock worth $280,475,000 after purchasing an additional 15,097 shares in the last quarter. Alberta Investment Management Corp grew its stake in shares of GALAPAGOS NV/S by 19.0% during the second quarter. Alberta Investment Management Corp now owns 77,588 shares of the biotechnology company’s stock valued at $15,307,000 after purchasing an additional 12,375 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of GALAPAGOS NV/S in the first quarter valued at approximately $2,323,000. Finally, Marshall Wace North America L.P. bought a new position in GALAPAGOS NV/S in the 2nd quarter worth approximately $1,180,000. Institutional investors own 11.58% of the company’s stock.
The stock has a market cap of $8.42 billion, a price-to-earnings ratio of 82.58 and a beta of 0.80. The company has a current ratio of 9.09, a quick ratio of 9.09 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $136.68 and a 200-day simple moving average of $183.40.
GALAPAGOS NV/S (NASDAQ:GLPG) last released its earnings results on Thursday, August 6th. The biotechnology company reported ($1.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.88). The firm had revenue of $129.53 million for the quarter, compared to the consensus estimate of $118.41 million. GALAPAGOS NV/S had a return on equity of 8.24% and a net margin of 8.13%. On average, equities analysts predict that GALAPAGOS NV/S will post -4.66 earnings per share for the current fiscal year.
GALAPAGOS NV/S Company Profile (NASDAQ:GLPG)
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Read More: How to calculate compound interest
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.